Longest Follow-Up for ICI Plus TKI Favours Treatment with Avelumab Plus Axitinib Combination versus Sunitinib in Patients with Advanced RCC By Ogkologos - February 11, 2025 468 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a final analysis of the JAVELIN Renal 101 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR COVID-19 Pandemic Halts Cancer Care and Damages Oncologists’ Wellbeing [ESMO Press... September 13, 2020 Cancer in My Community: The Roadblocks to Receiving Cancer Care in... September 23, 2021 Studies Provide First Evidence That Breastfeeding after Breast Cancer Is Safe September 8, 2024 ESMO Asia Congress 2023, 1-3 December 2023, Singapore November 24, 2023 Load more HOT NEWS Immunotherapy’s Skin Side Effects: Are Microbes to Blame? FDA Grants Accelerated Approval to Pembrolizumab for HER2-positive Gastric Cancer BRCA1/2 Pathogenic Variant Carriers with Serous Tubal Intraepithelial Carcinoma at Risk-Reducing... New Task Force Focuses on Quality of Life for AYAs with...
